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Abstract. Collagen VII is the major structural constitu- 
ent of anchoring fibrils in the skin. It is synthesized as a 
procollagen that is larger than the collagen deposited in 
the tissue. In this study, we investigated the conversion 
of procollagen VII to collagen VII in human skin and in 
cutaneous cells in vitro and identified the propeptide 
using domain-specific antibodies. For this purpose, two 
bacterial fusion proteins containing unique sequences 
of the carboxy-terminal globular NC-2 domain of pro- 
collagen VII were prepared, and polyclonal antibodies 
raised against them. Immunoblotting showed that the 
anti-NC-2 antibodies reacted with procollagen VII iso- 
lated from cultured keratinocytes, but not with collagen 
VII extracted from the skin. Immunohistochemical  ex- 
periments with the NC-2 antibodies revealed a strong 
reaction in cultured keratinocytes, but the basement 
membrane zone of normal skin remained negative. The 
staining could not be rendered positive by chemical or 
enzymatic unmasking of potential hidden epitopes in 
the skin, indicating that most of the NC-2 domain is ab- 
sent from normal skin. In contrast, a positive staining 
with NC-2 antibodies was observed in the skin of a pa- 
tient with dystrophic epidermolysis bullosa, who car- 
ried a 14-bp deletion at one of the intron-exon junc- 
tions of the collagen VII gene. This aberration led to an 
in-frame skipping of exon 115 from the mRNA and 
eliminated 29 amino acids from the NC-2 domain which 
include the putative cleavage site for the physiological 
processing enzyme, procollagen C-proteinase. The re- 
suits indicate that in normal human skin, the removal of 
the NC-2 domain from procollagen VII precedes its 
deposition at the dermal-epidermal junction. Further- 
more, they suggest that an aberration in the procol- 
lagen VII cleavage interferes with the normal fibrillo- 
genesis of the anchoring fibrils. 
CHORIN6 fibrils extend from the lamina densa of the 
epidermal basement membrane  to  the  papillary 
connective tissue, thus ensuring tight cohesion be- 
tween the basement membrane and the dermis in the skin. 
The main structural protein of the fibrils is collagen VII, a 
homotrimeric collagen containing three identical al(VII) 
chains  (4, 5, 31). This collagen  is synthesized mainly by 
epidermal keratinocytes (20, 30). The primary synthetic 
product is larger than the collagen deposited in the tissue, 
and has been called procollagen VII in analogy to other 
members of the collagen protein family (5, 18, 20). Each 
al chain of procollagen VII consists of a long central tri- 
ple-helical  domain with a  typical  collagenous -Gly-X-Y- 
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repeat sequence, a large globular NH2-terminal NC-1 do- 
main, and a small globular COOH-terminal NC-2 domain 
(24,  25). Based  on  the  cDNA-derived  amino  acid  se- 
quence, the following molecular masses have been calcu- 
lated for the three procollagen VII domains:  NC-1,  133 
kD; collagenous domain, 145 kD; and NC-2, ~18 kD (7, 
12). Rotary shadowing electron micrographs of anchoring 
fibrils from tissue extracts suggested that NC-2 cleavage is 
necessary  for correct assembly  of collagen  VII (24, 25). 
During fibrillogenesis,  collagen  VII molecules  form anti- 
parallel tail-to-tail  dimers with a small  carboxy-terminal 
overlap and with the amino termini pointing outwards (5, 
24, 31). The dimers then aggregate  laterally in a nonstag- 
gered manner into the anchoring fibrils. Although not all 
small globular domains were removed from collagen VII 
dimers isolated from epidermoid carcinoma cell lines, most 
dimers from amnion extracts contained only the large glob- 
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COOH-terminal  cleavage during the  assembly  and  pro- 
cessing of the molecules in the extracellular space (24, 25). 
However, other investigators suggested  that  the  procol- 
lagen to collagen conversion occurs through cleavage of 
amino-terminal sequences (22). Thus, the knowledge about 
the location and timing of the proteolytic process that con- 
verts procollagen to collagen VII is limited and controver- 
sial. In addition, a specific procollagen N- or C-proteinase 
catalyzing this process has not yet been identified. 
In  dystrophic epidermolysis bullosa  (EBD)  1,  a  genetic 
blistering disorder of the skin, minor trauma induces sepa- 
ration of the epidermis from the dermis. This tissue sepa- 
ration occurs below the basement membrane, at the level 
of the anchoring fibrils. Electron microscopic studies have 
revealed a variety of structural abnormalities of anchoring 
fibrils in EBD (2, 11).  In contrast to normal skin, where 
the anchoring fibrils are slender and cross-striated, EBD 
skin  can  present  with  broad  and  wispy  fibrils  without 
crossbanding,  with very short fibrils, or no fibrils at  all. 
These  observations,  together with  immunochemical  and 
cell biological studies defined collagen VII as a candidate 
molecule for abnormalities  in  EBD  (see  3),  and  in  line 
with these data, mutations have been identified in the gene 
for collagen VII, COL7A1 (8) in several EBD patients (6, 
14, 34). 
The  aim  of the  present study was  to characterize the 
physiological processing of procollagen VII and to identify 
the propeptide domain that  is  removed during this  pro- 
cess. We show that procollagen VII synthesized by human 
keratinocytes  in  vitro  contains  all  three  structural  do- 
mains. During the processing, a large part of the NC-2 do- 
main is cleaved off and is not present in the collagen VII 
molecules deposited in normal human skin. This is further 
attested by the fact that the NC-2 domain is retained in the 
skin  of  an  epidermolysis  bullosa  patient  who  carries  a 
splice-site mutation of the collagen VII gene that causes 
elimination of the putative NC-2 cleavage site encoded by 
exon 115. 
Materials and Methods 
Preparation and Purification of  Bacterial 
Fusion Proteins 
To obtain antibodies recognizing the NC-2 domain of procollagen VII, 
two different portions of the NC-2 domain were expressed as prokaryotic 
fusion proteins. Fusion protein NC2-I0 involved amino acids 2780-2944 
and fusion protein NC2-7 amino acids 2837-2944  of procoUagen VII (7) 
(Fig.  1). The corresponding cDNA was amplified by reverse transcriptase 
(RT)-PCR from RNA from normal human keratinocytes. Briefly, poly 
A+ RNA was reverse transcribed to cDNA using Moloney murine leuke- 
mia virus (M-MuLV) reverse transcriptase (Boehringer-Mannheim GmbH, 
Mannheim, Germany) and processed for cDNA amplification. 40 PCR cy- 
cles were run on a thermocycler using a  PCR amplification kit (Perkin 
Elmer Corp., Ueberlingen, Germany) with primers listed in Table I. The 
amplification conditions for both primer pairs consisted of a denaturing 
step at 95°C for 45 s, primer annealing at 60°C for 30 s, and extension at 
72°C for 45 s. The final extension was prolonged to 10 min. All reactions 
were performed in a  final reaction vol of 50  ixl. Resulting amplificates 
were digested with SfiI and NotI, run on an agarose gel, electroeluted, and 
1.  Abbreviations  used  in  this  paper:.  EBD,  dystrophic  epidermolysis 
bullosa; IF, immunofiuorescence staining; KGM, keratinocyte growth me- 
dium; RT, reverse transcriptase. 
subcloned in the SfiI/NotI restriction sites of pDS9 cassette (35).  The re- 
suiting constructs were sequenced over the ligation sites to confirm cor- 
rect in-frame cloning of the procollagen VII cDNA fragments. 
The fusion proteins were produced essentially as described by St0ber et 
al. (33). The constructs were transformed into M15(pREP4) cells, and the 
transformed cells were grown in Luria broth (LB) medium containing 100 
ixg/ml ampicillin and 25 ~g/ml kanamycin. Expression of the fusion pro- 
teins was induced by the addition of isopropyl 13-thiogalactopyranoside 
(Boehringer-Mannheim Corp.) to a final concentration of 2 mM. 3 h after 
induction, cells were centrifuged at 6,000 g for 10 min, and the pellet was 
extracted with 6 M guanidine-HC1 in 100 mM sodium phosphate, pH 8.0, 
containing i mM phenylmethylsulphonylfluoride for 1 h at 4°C. The solu- 
tion was cleared of debris by centrifugation at 10,000 g for 10 min, and the 
supernatant was directly applied to a 5-ml NiZ÷-NTA  agarose (OlAGEN 
Inc., Dtisseldorf, Germany) affinity column. After washing with 8 M urea 
in 100 mM sodium phosphate and 10 mM Tris, pH 8.0, the fusion proteins 
were eluted stepwise by lowering the pH to 6.3 and 5.9. Fractions were an- 
alyzed by SDS-PAGE and the fusion proteins were dialyzed against 4 M 
guanidine-HC1. 
Antibodies 
For immunization of New Zealand White rabbits, the fusion proteins were 
ethanol precipitated, suspended in PBS, and mixed with Freund's adju- 
vant according to standard immunization protocols (13).  The antibodies 
were affinity purified on nitrocellulose strips containing fusion proteins 
that were separated by SDS-PAGE and electrotransferred as described 
previously (4, 20). Polyclonal affinity-purified antibodies to the triple-heli- 
Figure 1.  Location of the fusion proteins within the NC-2 domain 
of procollagen VII.  (A)  A  schematic representation  of the  do- 
main structure of procollagen VII. The areas of the NC-2 domain 
corresponding  to  fusion  proteins  NC2-10  and  NC2-7  are  indi- 
cated by black bars. (B) The amino acid and nucleotide sequence 
of the  NC-2  domain  (7).  Vertical  line  with  the  double  arrow 
marks the border between the triple-helical domain and the NC-2 
domain. Arrowheads define fusion protein NC2-10. Amino acids 
covered  by  fusion  protein  NC2-7  are  underlined.  Asterisk  (*) 
shows the  putative  procollagen  C-proteinase cleavage  site. Nu- 
cleotides of exon 115 are shaded. 
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Primers for mutation analysis* 
Col 11 F: 5'AGGACGAATI'CTTGTGCGCCAAGAGATGAGTC 3' 
Coll0R: 5'CATGCAAGCTTGTCCCCTGGCTCTGGACCAC 3' 
ColE114:  5' CCAGTTCATCGCATCTGGATCAC 3' 
The PCR conditions  for the primers  are described in Materials and Methods. 
*  Primer NC2-reverse was used in combination  with both NC2-10 forward and NC2-7 forward. 
*The internal restriction sites are underlined: an EcoRI site in Col11F and a HindIIl site in Coll0R. 
cal domain of human collagen VII (4),  and the mAb LH-7.2 (23)  to the 
NC-1 domain of collagen VII were used as controls. The FITC- or biotin- 
labeled second antibodies were obtained from Dakopatts, Glostrup, Den- 
mark, peroxidase-labeled goat anti-rabbit antibodies from Kirkegaard & 
Perry Laboratories, Inc., Gaithersburg, MD, and streptavidin peroxidase 
and FITC-labeled streptavidin from Boehringer-Mannheim Corp. 
Immunofluorescence Staining (IF) 
IF staining of 5-1~m cryosections of adult human skin or semiconfluent hu- 
man keratinocytes on coverslips was carried out with standard techniques. 
For demasking of potentially hidden epitopes at the basement membrane 
zone, the cryosections were air dried, rinsed with TBS, and treated with 
0.1 M acetic  acid, 8 M urea, or 0.1%  trypsin for 30 min at room tempera- 
ture, or with 2% hyaluronidase for 1 h at room temperature. After these 
treatments the sections were washed extensively with TBS before IF staining. 
Keratinocyte Cultures 
Keratinocytes were cultured in serum-free keratinocyte growth medium 
(KGM) (Gibco Life  Technologies, Eggenstein, Germany) supplemented 
with bovine pituitary extract and EGF as described previously (20). For 
IF, cells were seeded on glass coverslips and grown to subconfluence. Two 
days before the staining or extraction of the cells, bovine pituitary extract 
and EGF were omitted from the medium, and 50 ~g/ml ascorbate, and in 
some experiments 5 ng/ml TGF-I3, were added daily. 
For some experiments, keratinocytes were grown on an extracellular 
matrix produced by fibroblasts. For this purpose, fibroblasts were culti- 
vated in DMEM/10% FCS to confluency and then incubated for 2-3 d in 
serum-free DMEM daily  supplemented with 50 ixg/ml ascorbate. The fi- 
broblasts were then removed by treating the cultures with 0.1%  Triton 
X-100  in PBS twice  for 10 min. The remaining extracellular matrix was 
washed extensively with  PBS  and  preincubated  in  KGM,  and  kerati- 
nocytes were seeded onto the preexisting matrix. 
Extraction of Procollagen and Collagen  VII 
For extraction of procollagen VII, the confluent keratinocyte layer was di- 
rectly solubilized in a buffer containing 8 M  urea, 2%  SDS, 0.1  M  1,4- 
dithiocrythritol, 0.1 M Tris-HC1  (pH 6.8), and a mixture of proteinase in- 
hibitors at a  final  concentration of 1 mM Pefabloc (Merck,  Darmstadt, 
Germany), 10 mM EDTA, 20 mM N-ethylmaleimide, and 100 mM ~-ami- 
nocaproic acid as described (20). Extraction of collagen VII from skin was 
carried out after splitting the skin through the lamina lucida  of the base- 
ment membrane with I M NaCI in TBS for 48 h (9) in the presence of pro- 
teinase inhibitors. The epidermis was mechanically separated from the 
dermis, and the newly exposed dermal layer was extracted with the above 
extraction buffer for 2 min at 95°C (4). 
Electrophoresis and Immunoblotting 
The samples were separated by SDS-PAGE under reducing conditions on 
polyacrylamide gradient gels. After electrotransfer onto nitrocellulose in 
the presence of 0.1%  SDS, the nitrocellulose sheet was incubated with the 
first antibodies overnight and with either peroxidase-labeled goat anti- 
rabbit IgG for 2 h, or biotin-labeled swine anti-rabbit IgG for 4 h, and 
streptavidin  peroxidase  for 2  h.  4-chloro-l-naphtol was used  as  chro- 
mogen. 
Epidermolysis BuUosa Patient 
The female patient was born with blisters over the trunk and the extremi- 
ties. The family history was free of skin diseases or genetic disorders. Blis- 
tering activity  diminished over the years resulting in a localized  EBD by 
the age of 12 yr. The blisters healed with scarfing and development of 
milia, Pasini papules, and nail dystrophy. The patient thus presented with 
the characteristic clinical phenotype of localized  dystrophic EB. Biopsies 
were obtained from clinically  unaffected perilesional skin. The diagnosis 
was confirmed with antigen mapping (2)  and electron microscopy using 
standard techniques. 
Detection and Characterization of a Mutation in the 
COL7AI Gene 
Total RNA was isolated from EBD and control fibroblasts with TRIzol 
reagent  according  to  the  manufacturer's specifications  (GIBCO  BRL, 
Gaithersburg, MD). The RNA was dissolved in RNase-free water in a 
concentration of i  I~g/l~l. Deoxyoligo-(dT)ls-primed eDNA synthesis was 
carried out with SuperScdptTUII reverse transcriptase essentially as de- 
scribed by the manufacturer (GIBCO BRL) but with the following excep- 
tions;  RNA was denatured with 100 pmol deoxyoligo(dT) at 90°C for 10 
min before primer extension which was performed at 50°C for i  h. 
Collagen  VII-specific primers were deduced  from Greenspan, 1993 
(12) and Christano et al., 1994 (7; These sequence data are available  from 
EMBL/GenBank under accession number L23982). The primer sequences 
are  listed  in Table  I. Primers Co111F and  Coll0R  flanking the  NC-2- 
encoding DNA sequence were designed with internal restriction sites. An 
internal  primer ColEl14  was designed  for restriction  fragment length 
polymorphism (RFLP)  analysis  and  for  DNA  sequencing of genomic 
clones. RT-PCR was performed with primers Co111F and Coll0R with the 
following cycling conditions:  denaturation at 95°C for 4 min and then 34 
cycles with 95°C for 1 min, 59°C for 1 min, 72°C for 2 min, and a final ex- 
tension at 72°C for 10 min. PCR on genomic DNA was performed with 
primers Co111F and Coll0R essentially as described above, but with 32 cy- 
cles and with extension time of 2 min and 30 s. The PCR products were 
purified  with  Qiaex  particles  (QIAGEN  Ltd.,  Dorking,  UK)  before 
EcoRI/HindIII digestion and ligation into EcoRI/HindIII-treated M13- 
mp19.  Recombinant clones were propagated  on JM101.  eDNA clones 
were sequenced with the  -40 M13  universal primer, whereas genomic 
clones were sequenced with primer Co1El14.  DNA sequencing was car- 
ried out with standard techniques using kit reagents (United States Bio- 
chemical Corp., Cleveland, OH). 
For RFLP analyses, PCR was performed on genomic DNA with primers 
Co1El14  and Coll0R with initial  denaturation for 4 min at 95°C followed 
by 30 cycles with 94°C for I min, 62°C for I min, 72°C for 2 min, and a final 
extension at 72°C for 10 min. PCR products were digested with PstI and 
SphI overnight and separated on a 3.5%  agarose gel according to the man- 
ufacturer's specifications  (MetaPhor; FMC BioProducts, Rockland, ME). 
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Expression of ProcoUagen VII NC-2 Fragments 
in Bacteria 
Bacterial fusion proteins corresponding  to  the  NC-2 do- 
main of procollagen VII were designed on the basis of the 
cDNA sequence and deduced amino acid sequence (7, 12) 
as shown in Fig. 1. The larger fragment, NC2-10, covered 
165  amino acids and corresponded to the entire globular 
sequence plus the four last amino acids of the triple-helical 
domain  (amino  acid  residues  2780-2944  of  procollagen 
VII, or nucleotides  8338-8832  of the  cDNA,  numbering 
according to ref. 7). The shorter fragment, NC2-7, was de- 
signed  to  correspond  to  the  most  COOH-terminal  se- 
quence of this globular domain, covering the last 108 car- 
boxy-terminal  amino  acids  of  the  procollagen,  residues 
2837-2944  (nucleotides 8509-8832 of the cDNA). Even if 
the  physiological  C-proteinase  cleavage  site  was  not  lo- 
cated immediately adjacent to the border of the triple heli- 
cal domain, antibodies to this latter sequence should still 
exclusively recognize the propeptide (see Fig. 1). 
Both plasmid constructs with the cDNA for NC-2 frag- 
ments could be efficiently expressed in bacteria. The fu- 
sion proteins were soluble in 6 M guanidin-HC1 and could 
be purified to homogeneity from cell extracts with a  one- 
step Ni2+-affinity chromatography. Usually 1 liter of bac- 
terial  cultures  yielded  ~4-20  mg of the  respective frag- 
ment.  Interestingly, the  mobility on SDS-PAGE of both 
fragments was slower than expected based on their molec- 
ular size (Fig. 2). The larger protein has a calculated mo- 
lecular  mass  of  ~20  kD  and  the  smaller  one  ~14  kD. 
However, they migrated with apparent molecular masses 
of 33 and 25 kD, respectively. 
Differential Reactivity with Procollagen and Collagen 
VII in Immunoblots 
Polyclonal  antibodies  were  raised  against  NC2-10  and 
NC2-7 fragments and  affinity purified on fusion proteins 
absorbed  to  nitrocellulose  strips.  As  expected,  the  anti- 
bodies  cross-reacted  with  either  polypeptide  in  ELISA 
and immunoblot assays (Table II). However, they showed 
different  reactivity to  procollagen  and  collagen  VII iso- 
lated from cultured keratinocytes or skin (Fig. 3).  In im- 
munoblots, antibodies to the fusion protein NC2-10 showed 
positive staining with procollagen VII from keratinocytes, 
collagen VII from the skin, as well as pepsin-treated col- 
lagen VII, which  contains  the  triple-helical  domain with 
only short noncollagenous sequences. In contrast, antibod- 
ies to the shorter NC2-7 fragment recognized procollagen 
Table II. Immunoreactivity of Domain-specific Antibodies to 
Procollagen VII 
Antibodies* 
Antigen/Tissue  NC2-7  NC2-10  Triple-helical  LH-7.2  EBA 
IF staining 
Keratinocytes  +  +  +  +  + 
Skin  -  +  +  +  + 
Immunoblot 
Procollagen VII 
(Keratinocyte extract)  +  +  +  +  + 
Collagen VII 
(Skin extract)  -  +  +  +  + 
Triple-helical 
domain  ~+  _  +  +  -  _ 
NC- 1 domain  ~  -  -  -  +  + 
NC2-7  +  +  -  -  - 
NC2-10  +  +  +  -  - 
* Polyclonal antibodies to the triple-helical domain were raised against pepsinized col- 
lagen VII (4). Monoclonal antibody LH-7.2 (23) and the EBA autoantiserum (10) rec- 
ognize the amino-terminal NC-1 domain. 
*The triple-helical domain was obtained with pepsin digestion of procollagen VII. 
~The NC-1 domain was obtained with digestion of procollagen VII with purified bac- 
terial collagenase. 
+, positive reaction; -, negative reaction. 
VII, but neither collagen VII nor pepsin-treated collagen 
VII (Fig. 3). Control antibodies to the triple-helical domain 
reacted  with  procollagen  VII, collagen  VII, and  pepsin- 
treated  collagen VII. The mAb LH-7.2 to  the  NC-1  do- 
main and autoimmune sera from patients with epidermol- 
ysis bullosa acquisita,  an acquired blistering  skin disease 
with autoantibodies reactive with the NC-1 domain (10), 
recognized both the  procollagen and  the  collagen forms, 
indicating that the NC-1 domain is part of the mature col- 
lagen VII molecule in the tissue (Table II). 
Immunostaining of Normal Control Skin 
In  IF staining  of normal  control  skin,  antibodies  to  the 
longer fusion protein NC2-10  produced  a  positive linear 
Figure 2.  Migration  of  fusion  pro- 
teins  on  SDS-PAGE.  The  fusion 
proteins  were  run  on  an  SDS- 
PAGE  with a  10-15%  gradient  gel. 
Lanes  1  and  2: NC2-7.  Lanes  4  and 
5:  NC2-10.  Lane  3:  globular  molec- 
ular mass  markers  from  top  to  bot- 
tom:  49.5,  32.5,  27.5,  and  18.5  kD. 
Positions  of these  markers  are  also 
indicated  on the right. 
Figure 3.  Specificity of fusion protein antibodies.  For immuno- 
blotting,  the antigens  were separated on an SDS-PAGE with a 
3-15% gradient  gel, and the blot was stained  with antibodies  to 
fusion protein NC2-7 (A), to the triple-helical domain of collagen 
VII (B), and to fusion protein NC2-10 (C). Lanes 1, 2, 5, 6, 9, 10: 
keratinocyte extract.  Lanes 3, 7, 11: skin extract.  Lanes 4, 8, 12: 
pepsinized  collagen  VII (triple-helical  fragment).  Arrowheads 
from top to bottom point to procollagen VII, collagen VII, and to 
the triple-helical fragment, respectively. 
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the reaction seen with antibodies  to the triple-helical  do- 
main of collagen VII (Table  II). In contrast, the reaction 
with  antibodies  to  the  shorter  fusion  protein  NC2-7  re- 
mained  negative,  indicating  that  all  or  the  majority  of 
epitopes  contained  in  the  fragment  NC2-7  were  absent 
from normal human skin (Fig. 4). This pattern was verified 
in  skin  from 50  different  normal  individuals  of different 
ages.  Only in  a  few  cases  was  a  very  faint  staining  ob- 
served. Unmasking of potential hidden epitopes with 8 M 
urea, 0.1 M  acetic acid, 0.1% trypsin, or 2% hyaluronidase 
did  not  render  positive  staining  in  normal  skin.  As  ex- 
pected,  cultured  human  keratinocytes  stained  positively 
with both antibodies indicating presence of newly synthe- 
sized procollagen VII in the cells (Fig. 4). 
Conversion of Procollagen  to Collagen  VII Is Efficient 
In Vivo but Inefficient In Vitro 
Extracts  of  cultured  human  keratinocytes  always  con- 
tained  procollagen  VII  but  no  collagen  VII,  and  con- 
versely, skin extracts contained collagen VII but no pro- 
collagen VII (Fig. 5 A). The extraction procedure included 
pretreatment  of the monolayer cell cultures with ascorbic 
acid in serum-free low-calcium medium for 48-72 h. Dur- 
ing this  time,  no significant conversion of procollagen to 
collagen VII took place.  Addition to the cultures  of sub- 
stances  that  are  known  to  enhance  conversion  of other 
procollagens  or other precursor proteins  to their  respec- 
tive  tissue  forms,  such  0.1%  dextran  sulphate,  1.5  mM 
calcium, or 50 IxM ZnCl2 (1, 28, 29), did not stimulate con- 
version of procollagen VII. Neither did culturing of kerati- 
Figure 4.  IF staining with fusion protein antibodies. Human kera- 
tinocytes  (a  and  b)  and  normal  control  skin  (c  and  d)  were 
stained with antibodies to the triple-helical  domain (a and c) and 
to fusion protein NC2-7 (b and d). Both antibodies stained kera- 
tinocytes. The control antibodies recognized collagen VII at the 
basement membrane zone of the skin, but the reaction with anti- 
bodies to NC2-7 remained negative, indicating absence of the NC-2 
domain from normal skin. Bars, a and b, 10 ~m; c and d, 50 ~m. 
Figure 5.  Procollagen to collagen VII conversion in vitro.  Cell 
and skin extracts were separated on SDS-PAGE with a 3-15% 
(A) or 3-10% (B) gradient gel, and immunoblotted with antibod- 
ies to the triple-helical  domain of collagen VII. (A) Procollagen 
VII isolated from keratinocytes grown on plastic  (lanes 1 and 2) 
and collagen VII isolated from the skin (lane 3). In the skin, only 
collagen VII is present, implying efficient conversion of procol- 
lagen in vivo. (B) In extracts of keratinocytes grown for 48 h on 
an extracellular matrix produced by fibroblasts (lanes 1 and 2), 
some conversion of procollagen VII (lane 4) to collagen VII (lane 
3)  can be  seen.  Arrow marks  procollagen, and  the  arrowhead 
marks collagen VII. On the right,  molecular mass markers are, 
from top to bottom, 205, 117, 80, and 50 kD. 
nocytes on plates coated with heparan sulphate or heparan 
sulphate  proteoglycan, treatment  of keratinocyte cultures 
with fibroblast extracts, or coculturing fibroblasts and ke- 
ratinocytes result in processing of procollagen VII. 
Under two different cell culture conditions, a  low level 
of procollagen to collagen VII conversion was observed. 
When keratinocytes  were  grown on an  extracellular  ma- 
trix that had been deposited by fibroblasts,  some process- 
ing of procollagen VII took place within 48 h  (Fig. 5 B). 
Addition of 5 ng/ml of TGF-f3 to the keratinocyte cultures 
(21) for 48 h  also induced conversion to some extent (not 
shown). Quantitation of the procollagen/collagen VII ratio 
in the immunoblots was not attempted, but the intensity of 
the collagen VII bands was always clearly less than that of 
procollagen VII bands, suggesting that maximally 20-30% 
of the procollagen in these cultures was processed to col- 
lagen VII. 
For skin organ culture experiments, the tissue was meta- 
bolically  labeled  with  [35S]methionine/cysteine  in  a  me- 
thionine-  and  cysteine-free  KGM  medium  overnight  at 
37°C. The tissue was extracted with the chaotropic extrac- 
tion buffer described  in  Materials  and Methods,  and the 
extracts  subjected  to  SDS-PAGE,  autoradiography,  and 
immunoblotting. In all experiments only collagen VII, but 
no procollagen VII was found (not shown), indicating that 
the processing occurs remarkably faster in the skin than in 
monolayer cell cultures.  The factors required  for an effi- 
cient processing in  vitro  remain  unknown  at  the  present 
time. 
Retention of the NC-2 Domain in the Skin of an EB 
Patient with a Mutation in the COL7A1 Gene 
In contrast to normal skin,  a  bright fluorescence was ob- 
served with antibodies to the NC2-7 fusion protein in the 
skin of a  patient  with localized EBD. This  indicated  that 
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of this patient (Fig. 6). Ultrastructural analysis of clinically 
unaffected  skin  showed  paucity of anchoring  fibrils.  On 
long streches of the basement membrane zone, no clearly 
defined fibrils could be discerned. However, at other loca- 
tions anchoring fibrils with a slightly diffuse structure and 
crossbanding could be seen (Fig. 7). 
RT-PCR analysis of the patient's fibroblast mRNA with 
primers ColllF  and  Coll0R  corresponding  to  the  NC-2 
domain  produced  two PCR  fragments, one  with the  ex- 
pected length and one shorter product. The apparent dif- 
ference in the length of the products was 80-90 bp (Fig. 8 
A). Sequencing of the cDNA revealed a deletion of 87 bp 
which  corresponded  exactly  to  exon  115,  indicating  in- 
frame skipping of this exon (Fig. 8 B). Exon 115 codes for 
amino  acids  2814-2843  of procollagen  VII  (see  Fig.  1). 
Since the  phase of the  intron-exon  boundaries  does not 
coincide  with the  reading frame of the  cDNA, the  exon 
skipping creates a new codon at the splice junction which 
codes for glutamine. Thereafter, the reading frame contin- 
ues normally. The resulting polypeptide is 29 amino acids 
shorter than the wild-type procollagen VII ctl chain. Using 
Figure  6.  Immunofluorescence staining  of  the  EBD  patient's 
skin. Antibodies to the NC2-7 fusion protein (a) and control anti- 
bodies to collagen  VII (b) showed  a linear fluorescence  at the 
dermo-epidermal basement membrane, indicating that in the pa- 
tient's skin  the NC-2  domain is retained.  Normal control skin 
showed negative reaction with the NC2-7 antibodies,  see Fig. 4 d. 
Bar, 50 Ixm. 
Figure  7.  Electron  microscopic  analysis  of the  EBD  patient's 
skin.  Ultrastructural  analysis  of clinically  uninvolved  skin  re- 
vealed paucity  of well-defined,  tightly packed anchoring  fibrils. 
Clearly identifiable  fibrils appeared somewhat diffuse and lacked 
a strong crossbanding  pattern (arrow). The other components of 
the dermal-epidermal basement membrane zone appeared nor- 
mal. Bar, 0.2 ixm. 
genomic PCR and restriction enzyme analysis we localized 
the genetic defect that leads to this exon skipping in the 
exon-intron junction of exon 115. We showed the aberra- 
tion is caused by a heterozygous 14-bp deletion in the pa- 
tient's collagen VII gene (Fig. 9, A  and B). 
Discussion 
Ample evidence exists for the  fact that  the  "cell culture 
form" of collagen VII is larger than the  "tissue form" (5, 
20, 24, 25). Rotary shadowing images of partially purified 
collagen  VII  preparations  isolated  from  carcinoma  cell 
lines or amnion demonstrated dimeric molecules with or 
without a small globular domain (24, 25). It seemed, there- 
fore, likely that  the  carboxy-terminal globular NC-2 do- 
main was removed during the procollagen to collagen con- 
version, but other evidence based on collagenase digestion 
of procollagen  VII from  keratinocyte  cultures  and  col- 
lagen VII from human skin pointed to processing at the 
amino terminus (22).  Since domain-specific antibodies to 
collagen VII were needed for the characterization of pro- 
collagen and collagen VII in skin, we prepared antibodies 
against  recombinant  collagen  VII  fragments  and  used 
them in immunohistochemical experiments. 
Two  different  recombinant  bacterial  fusion  proteins 
were  produced  that  corresponded  to  the  amino acid  se- 
quences  of the NC-2 domain  and included  in  addition  a 
21-amino acid leader peptide. The mobility of the purified 
fusion  proteins  on  SDS-PAGE  was  significantly  slower 
than expected from their deduced  amino acid sequences. 
The larger fusion protein with a calculated molecular mass 
of N20 kD migrated just below the 32.5-kD globular mo- 
lecular mass marker, and the shorter protein with a calcu- 
lated molecular mass of ~14 kD just  below the 27.5-kD 
marker. This observation is in line with the electrophoretic 
mobility estimates of the NC-2 domain isolated from pro- 
collagen VII using bacterial collagenase digestion. The ap- 
parent molecular mass was 32 kD (25), in spite of the fact 
that  the  domain only consists  of 161  amino acids  as de- 
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Agarose gel electrophoresis of products of RT-PCR of mRNA 
with primers Coil 1F and Coll0R. Std, molecular weight markers; 
Co,  control mRNA;  EB,  EBD  patient's mRNA. The patient's 
sample showed two PCR products, one of the expected size of 
439 kb (slender arrow), and one that was ,-,,80-90 bp shorter (fat 
arrow). On the outmost lanes as size markers a 1-kb DNA ladder 
(Gibco Life Technologies), and on the next lanes a 100-bp ladder, 
from  1,500  to  100  bp.  (B)  Nucleotide sequence  of the  cDNA. 
(Left) a normal control sequence. (Middle) sequence of the upper 
band of lane EB in A  (*), the patient's normal band. (Right) se- 
quence of the lower band of lane EB in A (*), the patient's abnor- 
mal band. Note that in the cDNA sequence of the lower band, 
exon 116 follows exon 114, indicating skipping of exon 115. 
Figure 9.  Deletion mutation in the collagen VII gene. (A) Ge- 
nomic PCR products were generated with primers ColEll4 and 
Coll0R, digested with PstI and SphI, and separated on a high res- 
olution agarose gel. Lane 1: size markers, 1-kb DNA ladder; lane 
2: size markers, a 100-bp ladder, from 1,500 to 100 bp; lane 3: ge- 
nomic DNA from a healthy unrelated control person; lane 4: ge- 
nomic DNA of the EBD patient. In the control, the restriction 
enzyme digestion generated four fragments: 422,  183,  166, and 
105 bp (arrowheads on the right, from top to bottom). In the pa- 
tient's sample, an additional band of ~150 bp (arrow) reflected a 
deletion in the gene. (B) Characterization of the mutant allele. 
DNA sequence of genomic DNA from a normal control individ- 
ual (left panel), of the EB patient's normal allele (middle panel) 
and the EB patient's mutant allele (right panel). The 14 bp de- 
leted from  the  mutant  allele are  shown  between  the  brackets 
(slender arrow). The exon 115-intron 115 junctions are indicated 
with fat arrows. 
duced from the cDNA sequence (7, 12). Posttranslational 
modifications  could  explain  this  apparent  discrepancy. 
The NC-2 domain contains four potential phosphorylation 
sites, but no potential sites for glycosylation (7,  12).  It is 
not known whether  the NC-2  domain is phosphorylated. 
However,  the  most  likely  explanation  seems  to  be  the 
highly acidic nature of this domain which has a theoretical 
isoelectric point value of 4.3 (12), since overestimation of 
apparent size by SDS-PAGE has previously been reported 
for proteins rich in acidic residues (19). 
Antibodies to the longer fusion protein NC2-10 that cor- 
responds  to  the  entire  NC-2  domain  plus  the  four  last 
amino acid residues of the triple helix reacted with procol- 
lagen VII, collagen VII, and even with pepsinized collagen 
VII. Therefore,  these antibodies were  not useful for dis- 
tinction  between  procollagen  and  collagen VII.  Instead, 
the  antibodies  to  the  shorter  fusion  protein  NC2-7  that 
covered the  COOH-terminal  two-thirds of the NC-2  do- 
main, exclusively recognized procollagen VII. These anti- 
bodies did not react with normal control skin from 50 indi- 
viduals,  indicating that  all  of the  sequences  included  in 
NC2-7 were removed during the physiological processing 
before deposition of collagen VII onto the dermo-epider- 
mal basement membrane in the skin. 
The reaction patterns of these antibodies also deliver in- 
formation  about  the  physiological cleavage  site.  This  is 
likely to be localized within a  57-amino acid segment be- 
tween  residues  2780  and  2837  of procollagen VII,  since 
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NC2-7 (see Fig. 1). Antibodies to the longer fusion protein 
react with collagen VII, but antibodies to the shorter one 
do  not.  Within  this  region  resides  an  Ala-Asp  peptide 
bond at position 2821-2822, the only such bond within the 
NC-2 domain. The procollagen C-proteinase that cleaves 
the carboxy-terminal propeptides from procollagens I, II, 
and III also cleaves an Ala-Asp peptide bond (15). The 
amino  acid  sequences  flanking  the  2821-2822  peptide 
bond in procollagen VII  are also similar to those found 
around the cleavage site in procollagens I, II, and III (16, 
17),  making this Ala-Asp bond a candidate cleavage site 
for procollagen VII C-proteinase. 
Identification of the naturally cleaved peptide bond us- 
ing  protein  chemical  analysis  such  as  NH2-terminal  se- 
quencing of the cleavage product has not been possible be- 
cause of the extremely low quantities of procollagen VII 
and collagen VII in cell cultures, and susceptibility of this 
protein to unspecific proteolytic degradation during exten- 
sive  purification procedures.  However, we  present  here 
genetic  evidence  that  supports  the  assumption  of  the 
cleavage site within the first 53 amino acids of the NC-2 
domain, probably at position 2821-2822. A deletion in the 
COL7A1 gene that causes in-frame skipping of exon 115 
(see Fig. 1) results in lack of processing of procollagen VII. 
Exon 115 encodes amino acids 2814-2843 within the NC-2 
domain. Within this sequence resides the putative cleav- 
age site for the physiological procollagen C-proteinase, an 
Ala-Asp bond at position 2821-2822. 
In vitro, the conversion of procollagen to collagen VII is 
very slow and also dependent on experimental conditions. 
Some conversion takes place in keratinocytes cultured on 
a matrix that has been produced by fibroblasts, but no con- 
version occurs in cultures on plastic with or without addi- 
tion of dextran sulphate,  a  substance that has been suc- 
cessfully used to enhance processing of procollagen I  or 
profibrillin I in fibroblast cultures (1, 29). Analogous very 
slow conversion has been observed for laminin 5 (kalinin), 
another  structural  component  of  the  dermo--epidermal 
basement  membrane zone that  is  synthesized as  a  high 
molecular weight precursor and processed before forma- 
tion of suprastructures in vivo (26). Also laminin 5 pro- 
cessing takes place in skin organ cultures, but not in mono- 
layers. A  possible explanation for the efficient conversion 
of laminin 5 or procollagen VII in organ cultures is a high lo- 
cal concentration of the processing proteinases in the tissue. 
The function of the NC-2 domain is not known. Interest- 
ingly, the amino acid sequence of the NC-2 domain con- 
tains a Kunitz-type proteinase inhibitor motif (12). There- 
fore, it would be tempting to speculate about a feedback 
inhibition exerted by the cleaved propeptide on the spe- 
cific C-proteinase or other inhibitory activity towards tis- 
sue proteinases. A  similar Kunitz-type inhibitor motif is 
found in the COOH-terminus of the a3 chain of collagen 
VI, which is  also proteolytically processed before tissue 
deposition (27). However, a recombinant Kunitz domain 
of collagen VI a3 chain did not show proteinase inhibitor 
activity for several proteolytic enzymes (27). 
Since it was postulated that the NC-2 domain mediates 
dimerization  of  procollagen  VII  before  polymerization 
into anchoring fibrils, the postulate also predicted that mu- 
tations will affect processing of the collagen VII (25). Here 
we present a heterozygous deletion mutation that affects 
this  process in  a  patient  with  localized EBD.  Since the 
proband is the only affected individual in the family, it re- 
mains to be seen if this mutation is recessive or dominant. 
Abnormal COOH-terminal processing of procollagen VII 
might be analogous to other hereditary collagen diseases, 
Ehlers-Danlos  syndromes  type  VII  A  and  B,  in  which 
NH2-terminal processing of procollagen I is inhibited due 
to genetically altered amino acid sequence of the proal(I) 
or proa2(I) chains (32). It was speculated that for sterical 
reasons the molecules containing pros(l) chains would in- 
terfere with fibrillogenesis and cross-linking of collagen I. 
The  anchoring  fibrils  in  the  skin  of  the  present  EBD 
proband  were reduced in  number and  exhibited diffuse 
crossbanding,  but  not  other  gross  morphological  alter- 
ations. This ultrastructural finding is not specific, but could 
indicate defective lateral aggregation of collagen VII dimers. 
The  exact  molecular  mechanisms  leading  to  this  ultra- 
structure remain an open question at present. The deletion 
of 29 amino acids and the retention of the NC-2 domain of 
procollagen VII could be involved in the pathogenesis of 
the present case through sterical hindrance of collagen VII 
fibrillogenesis, through interference and destabilization of 
dimer formation, or perhaps have no effect at the forma- 
tion and stability of anchoring fibrils. Future characteriza- 
tion of the same or similar mutations in other families with 
more family members  and  affected individuals  will  help 
clarify the exact role of the NC-2 domain for the dimeriza- 
tion of procollagen VII and during fibrillogenesis and mat- 
uration of the anchoring fibrils. 
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